Platinum-resistant ovarian cancer: lines of therapy
5 standard-of-care settings across 3 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Third line and beyond
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Later lines | Clinical trials of antibody-drug conjugates against CDH6, folate receptor alpha, B7-H4 and TROP2; hormonal therapy in receptor-positive low-grade disease. | 85 |
Special situations
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Supportive care | Early palliative care, drainage of ascites, management of bowel obstruction and nutritional support alongside anticancer treatment. | - |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Any expression status | Relacorilant with nab-paclitaxel (ROSELLA); or single-agent weekly paclitaxel, pegylated liposomal doxorubicin, topotecan or gemcitabine with bevacizumab if bevacizumab-naive (AURELIA). | 98 | ||
| FRα | Folate receptor alpha-high | Mirvetuximab soravtansine with ophthalmic monitoring (MIRASOL). | 98 | ||
| PD-L1 | PD-L1 CPS 1 or more | Pembrolizumab with weekly paclitaxel, with bevacizumab where not previously given (KEYNOTE-B96). | 98 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.